Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib after nephrectomy for renal cell carcinoma
ACTRN12609000048280Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Placebo for 3 years, Sorafenib for 1 year then placebo for 2 years and Sorafenib for 3 years (3 arms). Primary endpoint: Disease-free survival. Started Jun 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ACTRN12609000048280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000048280.